WO2002075318A3 - Neurofibrillary labels - Google Patents
Neurofibrillary labels Download PDFInfo
- Publication number
- WO2002075318A3 WO2002075318A3 PCT/GB2002/001318 GB0201318W WO02075318A3 WO 2002075318 A3 WO2002075318 A3 WO 2002075318A3 GB 0201318 W GB0201318 W GB 0201318W WO 02075318 A3 WO02075318 A3 WO 02075318A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tau
- tau protein
- derivative
- ligands
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/20—[b, e]-condensed with two six-membered rings with hydrogen atoms directly attached to the ring nitrogen atom
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/583—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with non-fluorescent dye label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Lubricants (AREA)
Abstract
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2440794A CA2440794C (en) | 2001-03-20 | 2002-03-20 | Neurofibrillary labels |
AT02720102T ATE556323T1 (en) | 2001-03-20 | 2002-03-20 | NEUROFIBRILLAR MARKERS |
AU2002251172A AU2002251172B2 (en) | 2001-03-20 | 2002-03-20 | Neurofibrillary labels |
JP2002573679A JP4288073B2 (en) | 2001-03-20 | 2002-03-20 | Neurofibril label |
EP02720102A EP1421389B1 (en) | 2001-03-20 | 2002-03-20 | Neurofibrillary labels |
DK02720102.9T DK1421389T3 (en) | 2001-03-20 | 2002-03-20 | Neurofibril markers |
ES02720102T ES2386773T3 (en) | 2001-03-20 | 2002-03-20 | Neurofibrillar markers |
US10/665,008 US7335652B2 (en) | 2001-03-20 | 2003-09-22 | Neurofibrillary labels |
HK04103802.8A HK1062044A1 (en) | 2001-03-20 | 2004-05-27 | Neurofibrillary labels |
US12/071,693 US7713962B2 (en) | 2001-03-20 | 2008-02-25 | Neurofibrillary labels |
US12/662,887 US8097615B2 (en) | 2001-03-20 | 2010-05-10 | Neurofibrillary labels |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0106953.3 | 2001-03-20 | ||
GBGB0106953.3A GB0106953D0 (en) | 2001-03-20 | 2001-03-20 | Neufofibrillary labels |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/665,008 Continuation US7335652B2 (en) | 2001-03-20 | 2003-09-22 | Neurofibrillary labels |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002075318A2 WO2002075318A2 (en) | 2002-09-26 |
WO2002075318A3 true WO2002075318A3 (en) | 2004-03-11 |
Family
ID=9911161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2002/001318 WO2002075318A2 (en) | 2001-03-20 | 2002-03-20 | Neurofibrillary labels |
Country Status (13)
Country | Link |
---|---|
US (3) | US7335652B2 (en) |
EP (1) | EP1421389B1 (en) |
JP (2) | JP4288073B2 (en) |
CN (2) | CN1578910A (en) |
AT (1) | ATE556323T1 (en) |
AU (1) | AU2002251172B2 (en) |
CA (1) | CA2440794C (en) |
DK (1) | DK1421389T3 (en) |
ES (1) | ES2386773T3 (en) |
GB (1) | GB0106953D0 (en) |
HK (1) | HK1062044A1 (en) |
PT (1) | PT1421389E (en) |
WO (1) | WO2002075318A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8697708B2 (en) | 2010-09-15 | 2014-04-15 | F. Hoffmann-La Roche Ag | Azabenzothiazole compounds, compositions and methods of use |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
GB0106953D0 (en) * | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
GB0113121D0 (en) | 2001-05-30 | 2001-07-18 | Univ Leeds | Biologically active photosensitisers |
GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
CA2529854A1 (en) * | 2003-06-19 | 2004-12-29 | Neuronautics, Inc. | Methods for inhibiting or reversing tau filament fibrillization |
GB0322756D0 (en) * | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
EP1799662B1 (en) | 2004-09-23 | 2013-04-17 | Wista Laboratories Ltd. | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
JP5186212B2 (en) | 2004-09-23 | 2013-04-17 | ウィスタ ラボラトリーズ リミテッド | Method for chemical synthesis and purification of diaminophenothiazinium compounds such as methylthioninium chloride (MTC) |
PT2004155T (en) | 2006-03-29 | 2018-05-02 | Wista Lab Ltd | Inhibitors of protein aggregation |
ES2659030T3 (en) * | 2006-03-29 | 2018-03-13 | Wista Laboratories Ltd. | Thioninium compounds and their use |
PT2013191E (en) | 2006-03-29 | 2010-10-29 | Wista Lab Ltd | 3,7-diamino-10h-phenothiazine salts and their use |
JP5132090B2 (en) * | 2006-06-16 | 2013-01-30 | 東和薬品株式会社 | Epinastine hydrochloride dry syrup |
DK3121169T3 (en) | 2006-07-11 | 2022-02-28 | Wista Lab Ltd | Methods for the synthesis and / or purification of diaminophenothiazinium compounds |
CA3027974C (en) | 2007-10-03 | 2022-03-15 | Wista Laboratories Ltd. | Therapeutic use of diaminophenothiazines |
WO2009117042A1 (en) * | 2008-03-21 | 2009-09-24 | Adlyfe, Inc. | Use of pyrene to carry non-peptide agents across the blood brain barrier |
AU2009226161A1 (en) * | 2008-03-21 | 2009-09-24 | Adlyfe, Inc. | Use of pyrene to carry peptides across the blood brain barrier |
SI2338059T1 (en) * | 2008-09-23 | 2015-08-31 | Wista Laboratories Ltd. | Ligands for aggregated tau molecules |
DK3689346T3 (en) | 2008-12-10 | 2024-02-26 | Wista Lab Ltd | 3,6-disubstituted xanthylium salts for the treatment of tauopathy |
US8703952B2 (en) | 2008-12-12 | 2014-04-22 | Wista Laboratories Ltd. | Synthesis of 9-(arylalkyl)-1,2,3,4-tetrahydro-γ-carboline and analogues and intermediates |
CU23844B1 (en) | 2009-04-17 | 2012-10-15 | Ct De Neurociencias De Cuba | PROCEDURE FOR OBTAINING NEW DERIVATIVES OF NAFTALENE FOR THE LIVE DIAGNOSIS OF ALZHEIMER'S DISEASE |
WO2010130977A1 (en) | 2009-05-12 | 2010-11-18 | Wista Laboratories Ltd. | Methods of chemical synthesis of diaminophenothiazinium compounds involving the use of persulfate oxidants |
JP5868955B2 (en) | 2010-04-30 | 2016-02-24 | プロセッタ アンチバイラル インコーポレイテッド | Antiviral compounds |
EP2640703A1 (en) * | 2010-11-16 | 2013-09-25 | GE Healthcare UK Limited | Heterocyclic compounds as imaging probes of tau pathology |
JP6093707B2 (en) | 2010-11-30 | 2017-03-08 | ウィスタ ラボラトリーズ リミテッド | Compound preparation |
EP2670434B1 (en) | 2011-01-31 | 2018-12-26 | Tau Bio-Logic Corp. | Treatment of tauopathies |
WO2012107706A1 (en) | 2011-02-11 | 2012-08-16 | Wista Laboratories Ltd. | Phenothiazine diaminium salts and their use |
EP2699241B1 (en) | 2011-04-20 | 2016-07-27 | Prosetta Antiviral Inc. | Antiviral compounds |
US9464064B2 (en) | 2011-09-07 | 2016-10-11 | University Of Kansas | HCV helicase inhibitors and methods of use thereof |
CN102942537B (en) * | 2012-11-09 | 2014-07-02 | 浙江大学 | Benzothiazole-aniline compound used as pH fluorescent probe and preparation method thereof |
US9296754B2 (en) | 2013-03-15 | 2016-03-29 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
WO2014151729A1 (en) | 2013-03-15 | 2014-09-25 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
US9233961B2 (en) | 2013-03-15 | 2016-01-12 | Novartis Ag | Compounds and compositions for the treatment of parasitic diseases |
US9588129B2 (en) | 2013-03-15 | 2017-03-07 | Amira Medical Technologies Inc. | Methods for analyzing blood to detect diseases associated with abnormal protein aggregation |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
US10765755B1 (en) | 2013-11-20 | 2020-09-08 | University Of South Florida | Preparation and characterization of methylene blue nanoparticles for Alzheimer's disease and other tauopathies |
SI3083627T1 (en) | 2013-12-19 | 2019-01-31 | Novartis Ag | (1,2,4)triazolo(1,5-a)pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis |
CN107163022B (en) * | 2016-03-07 | 2021-07-16 | 上海如絮生物科技有限公司 | Isoquinoline compound, intermediate, preparation method and application thereof |
KR20230127371A (en) * | 2016-11-01 | 2023-08-31 | 아비나스 오퍼레이션스, 인코포레이티드 | Tau-protein targeting protacs and associated methods of use |
SE540570C2 (en) * | 2017-07-14 | 2018-10-02 | A method for analyzing the 3d structure of biomolecules | |
US11220515B2 (en) | 2018-01-26 | 2022-01-11 | Yale University | Imide-based modulators of proteolysis and associated methods of use |
CN113874078A (en) | 2019-04-05 | 2021-12-31 | Tauc3生物制品有限公司 | anti-TAUC 3antibody and application thereof |
GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
WO2021011913A1 (en) | 2019-07-17 | 2021-01-21 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
CN118059104A (en) | 2019-12-19 | 2024-05-24 | 阿尔维纳斯运营股份有限公司 | Compounds and methods for targeted degradation of androgen receptor |
GB202010652D0 (en) | 2020-07-10 | 2020-08-26 | Wista Lab Ltd | Anti-tau antibodies |
GB202010620D0 (en) | 2020-07-10 | 2020-08-26 | Wista Lab Ltd | System |
KR20240134174A (en) | 2022-01-12 | 2024-09-06 | 지틴벤트 리미티드 | Method for detecting tau protein in saliva samples |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1302250C (en) * | 1986-04-04 | 1992-06-02 | Khalid Iqbal | Diagnostic for alzheimer's disease |
WO1993003369A1 (en) * | 1991-08-01 | 1993-02-18 | Voorheis Paul H | Diagnostic method for alzheimer's disease |
WO1996004915A1 (en) * | 1994-08-08 | 1996-02-22 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes |
WO1996005837A1 (en) * | 1994-08-25 | 1996-02-29 | Bayer Aktiengesellschaft | Use of n-substituted phenothiazines |
WO1996030766A1 (en) * | 1995-03-27 | 1996-10-03 | F. Hoffmann-La Roche Ag | Inhibition of tau-tau-association |
EP1048302A2 (en) * | 1999-04-30 | 2000-11-02 | Pfizer Products Inc. | Radiotracers for in vivo study of acetylcholinesterase and Alzheimer's disease |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2815926A1 (en) * | 1978-04-13 | 1979-10-18 | Boehringer Mannheim Gmbh | NEW CARBAZOLYL- (4) -OXY-PROPANOLAMINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
EP0287909B1 (en) * | 1987-04-08 | 1992-09-02 | Salutar, Inc. | Amyloidosis and alzheimer's disease diagnostic assay and reagents therefor |
US5008099A (en) * | 1987-04-08 | 1991-04-16 | Salutar, Inc. | Amyloidosis and Alzheimer's disease diagnostic assay and reagents therefor |
GB8724412D0 (en) | 1987-10-19 | 1987-11-25 | Medical Res Council | Protein |
FI101344B (en) * | 1988-03-31 | 1998-06-15 | Tanabe Seiyaku Co | The method comprises preparing a preparation from which a pharmaceutically active substance is released in a controlled manner |
WO1993001348A1 (en) | 1991-07-10 | 1993-01-21 | Minnesota Mining And Manufacturing Company | Fluorochemical water- and oil- repellent treating compositions |
EP0909814B1 (en) | 1991-12-06 | 2008-02-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of protein kinases for the diagnosis and treatment of Alzheimer's disease |
WO1993019143A1 (en) * | 1992-03-17 | 1993-09-30 | Lord Corporation | Colorant-containing electrorheological materials |
US5536761A (en) * | 1992-12-07 | 1996-07-16 | Sakura Color Products Corporation | Water base dye ink composition |
GB9317193D0 (en) | 1993-08-18 | 1993-10-06 | Zeneca Ltd | Method |
US5697985A (en) * | 1995-06-07 | 1997-12-16 | Bayer Corporation | Process for the preparation storage-stable dye dispersions |
AU4322999A (en) | 1998-06-01 | 1999-12-20 | Advanced Research And Technology Institute, Inc. | Methods and compositions for diagnosing tauopathies |
JP2000344684A (en) | 1999-03-26 | 2000-12-12 | Bf Kenkyusho:Kk | Graphic diagnosis probe for disease accepting accumulating amyloid by pyronine b analog compound and composition for graphic diagnosis containing the same |
JP2000344685A (en) | 1999-03-26 | 2000-12-12 | Bf Kenkyusho:Kk | Graphic diagnosis probe for disease accepting accumulating amyloid by azure a analog compound and composition for graphic diagnosis containing the same |
AU2001244549A1 (en) | 2000-03-22 | 2001-10-03 | Bf Research Institute, Inc. | Azure a analogues useful as probes in the diagnostic imaging for diseases due toaccumulation of amyloid and compositions for diagnostic imaging containing the analogues |
AU8670201A (en) | 2000-08-24 | 2002-03-04 | Univ Pittsburgh | Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
GB0106953D0 (en) * | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
GB0117326D0 (en) | 2001-07-16 | 2001-09-05 | Univ Aberdeen | Napthoquinone-type inhibitors of protein aggregation |
US6953974B2 (en) * | 2003-08-26 | 2005-10-11 | Texas Instruments Incorporated | EEPROM device and method for providing lower programming voltage |
GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
EP1799662B1 (en) | 2004-09-23 | 2013-04-17 | Wista Laboratories Ltd. | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
-
2001
- 2001-03-20 GB GBGB0106953.3A patent/GB0106953D0/en not_active Ceased
-
2002
- 2002-03-20 PT PT02720102T patent/PT1421389E/en unknown
- 2002-03-20 AU AU2002251172A patent/AU2002251172B2/en not_active Expired
- 2002-03-20 DK DK02720102.9T patent/DK1421389T3/en active
- 2002-03-20 EP EP02720102A patent/EP1421389B1/en not_active Expired - Lifetime
- 2002-03-20 ES ES02720102T patent/ES2386773T3/en not_active Expired - Lifetime
- 2002-03-20 CA CA2440794A patent/CA2440794C/en not_active Expired - Lifetime
- 2002-03-20 JP JP2002573679A patent/JP4288073B2/en not_active Expired - Lifetime
- 2002-03-20 CN CN02810291.6A patent/CN1578910A/en active Pending
- 2002-03-20 AT AT02720102T patent/ATE556323T1/en active
- 2002-03-20 WO PCT/GB2002/001318 patent/WO2002075318A2/en active Application Filing
- 2002-03-20 CN CN200810185342.XA patent/CN101696977B/en not_active Expired - Lifetime
-
2003
- 2003-09-22 US US10/665,008 patent/US7335652B2/en not_active Expired - Lifetime
-
2004
- 2004-05-27 HK HK04103802.8A patent/HK1062044A1/en not_active IP Right Cessation
-
2008
- 2008-02-25 US US12/071,693 patent/US7713962B2/en not_active Expired - Lifetime
- 2008-09-24 JP JP2008243567A patent/JP2009035566A/en active Pending
-
2010
- 2010-05-10 US US12/662,887 patent/US8097615B2/en not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1302250C (en) * | 1986-04-04 | 1992-06-02 | Khalid Iqbal | Diagnostic for alzheimer's disease |
WO1993003369A1 (en) * | 1991-08-01 | 1993-02-18 | Voorheis Paul H | Diagnostic method for alzheimer's disease |
WO1996004915A1 (en) * | 1994-08-08 | 1996-02-22 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes |
WO1996005837A1 (en) * | 1994-08-25 | 1996-02-29 | Bayer Aktiengesellschaft | Use of n-substituted phenothiazines |
WO1996030766A1 (en) * | 1995-03-27 | 1996-10-03 | F. Hoffmann-La Roche Ag | Inhibition of tau-tau-association |
EP1048302A2 (en) * | 1999-04-30 | 2000-11-02 | Pfizer Products Inc. | Radiotracers for in vivo study of acetylcholinesterase and Alzheimer's disease |
Non-Patent Citations (7)
Title |
---|
CONDAMINES O ET AL: "New immunoassay for the mapping of neurofibrillary degeneration in Alzheimer's disease using two monoclonal antibodies against human paired helical filament tau proteins.", NEUROSCIENCE LETTERS. IRELAND 9 JUN 1995, vol. 192, no. 2, 9 June 1995 (1995-06-09), pages 81 - 84, XP002266004, ISSN: 0304-3940 * |
DATABASE WPI Section Ch Week 199228, Derwent World Patents Index; Class B04, AN 1992-226472, XP002266008 * |
DEZUTTER N A ET AL: "99mTc-MAMA-chrysamine G, a probe for beta-amyloid protein of Alzheimer's disease.", EUROPEAN JOURNAL OF NUCLEAR MEDICINE. GERMANY NOV 1999, vol. 26, no. 11, November 1999 (1999-11-01), pages 1392 - 1399, XP002266003, ISSN: 0340-6997 * |
LAI ROBERT Y K ET AL: "Examination of phosphorylated tau protein as a PHF-precursor at early stage Alzheimer's disease", NEUROBIOLOGY OF AGING, vol. 16, no. 3, 1995, pages 433 - 445, XP002266007, ISSN: 0197-4580 * |
MENA RAUL ET AL: "Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease", ACTA NEUROPATHOLOGICA, vol. 91, no. 6, 1996, pages 633 - 641, XP002266006, ISSN: 0001-6322 * |
MUKAETOVA-LADINSKA ELIZABETA B ET AL: "Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease", AMERICAN JOURNAL OF PATHOLOGY, vol. 157, no. 2, August 2000 (2000-08-01), pages 623 - 636, XP002266005, ISSN: 0002-9440 * |
SMITH C ET AL: "The molecular pathology of Alzheimer's disease: are we any closer to understanding the neurodegenerative process?", NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, BLACKWELL SCIENTIFIC PUBLICATIONS, LONDON, GB, vol. 20, no. 4, 1 August 1994 (1994-08-01), pages 322 - 338, XP002001576, ISSN: 0305-1846 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8697708B2 (en) | 2010-09-15 | 2014-04-15 | F. Hoffmann-La Roche Ag | Azabenzothiazole compounds, compositions and methods of use |
Also Published As
Publication number | Publication date |
---|---|
CA2440794C (en) | 2012-05-01 |
CN1578910A (en) | 2005-02-09 |
DK1421389T3 (en) | 2012-08-13 |
US7713962B2 (en) | 2010-05-11 |
JP2009035566A (en) | 2009-02-19 |
ES2386773T3 (en) | 2012-08-30 |
PT1421389E (en) | 2012-07-10 |
US20100285605A1 (en) | 2010-11-11 |
JP2004537034A (en) | 2004-12-09 |
CN101696977A (en) | 2010-04-21 |
AU2002251172B2 (en) | 2007-12-06 |
EP1421389B1 (en) | 2012-05-02 |
CA2440794A1 (en) | 2002-09-26 |
CN101696977B (en) | 2014-02-19 |
JP4288073B2 (en) | 2009-07-01 |
HK1062044A1 (en) | 2004-10-15 |
US20080219929A1 (en) | 2008-09-11 |
WO2002075318A2 (en) | 2002-09-26 |
EP1421389A2 (en) | 2004-05-26 |
US20040213736A1 (en) | 2004-10-28 |
GB0106953D0 (en) | 2001-05-09 |
ATE556323T1 (en) | 2012-05-15 |
US8097615B2 (en) | 2012-01-17 |
US7335652B2 (en) | 2008-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002075318A3 (en) | Neurofibrillary labels | |
Yen et al. | Characterizing closely spaced, complex disulfide bond patterns in peptides and proteins by liquid chromatography/electrospray ionization tandem mass spectrometry | |
WO2002016412A3 (en) | Binding polypeptides for b lymphocyte stimulator protein (blys) | |
WO2003039467A3 (en) | Monoclonal antibodies specific for beta-amyloid. | |
US20220299527A1 (en) | Methods to detect mtbr tau isoforms and use thereof | |
WO2006091214A3 (en) | Fluorescent isotope tags and their method of use | |
WO2004055519A3 (en) | Specific markers for pancreatic cancer | |
WO2006107962A3 (en) | Methods and products for evaluating an immune response to a therapeutic protein | |
Seiler | Chromatography of biogenic amines. I. Generally applicable separation and detection methods | |
Calvano et al. | Optimization of analytical and pre-analytical conditions for MALDI-TOF-MS human urine protein profiles | |
DK1075277T4 (en) | Methods for detecting and inhibiting angiogenesis | |
WO2001018550A3 (en) | Determination of adrenomedullin-binding proteins | |
WO2005116640A3 (en) | Identification of anti-prion drugs by high-throughput screening based on sift | |
HK1097908A1 (en) | Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer | |
WO2001011360A3 (en) | Relaxation of birefringence of magnetic nanoparticles during binding reactions | |
WO2002004949A3 (en) | Reagents and methods for identification of binding agents | |
WO2004070025A3 (en) | Novel goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders | |
MY148511A (en) | Neurofibrillary labels | |
JP2015505055A (en) | SRM / MRM assay for insulin receptor protein | |
DE60041582D1 (en) | METHOD FOR DETECTING INSUFFICIENT BINDING OF MAGNESIUM TO CELLULAR MEMBRANES FOR DISEASE IDENTIFICATION | |
WO2002058533A3 (en) | Process for determining target function and identifying drug leads | |
EP1265073A3 (en) | Methods for determining plasma free drug concentration | |
Hušek et al. | Rapid screening of urinary proline–hydroxyproline dipeptide in bone turnover studies | |
WO2002056236A3 (en) | Classification of polypeptides by ligand geometry and related methods | |
EP1722818A4 (en) | Photoreactive compound specifically binding to calcium binding proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2440794 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 01178/KOLNP/2003 Country of ref document: IN Ref document number: 1179/KOLNP/2003 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10665008 Country of ref document: US Ref document number: 2002573679 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002720102 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002251172 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 028102916 Country of ref document: CN |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2002720102 Country of ref document: EP |